Researchers from the Guangzhou Medical University used a gene editing technique named CRISPR/Cas to replace the CCR5 gene in 26 human embryos with an HIV-resistant mutation. Only four embryos were successfully edited, while the other 22 cases failed to produce the desired results.
The research was published in the Journal of Assisted Reproduction and Genetics.
"In this study, we demonstrated that the HIV-resistant mutation could be introduced into early human embryos through the CRISPR system," said Fan Yong, a researcher of the Guangzhou Medical University and an author of the paper was quoted as saying by state-run China Daily.
Since then, scientists from across the globe have been using the technology to edit animals' gene in the laboratory.
Huang Junjiu, a biologist at Sun Yat-Sen University in Guangzhou, was the first to apply the technique to humans. He reported his experiment on 71 human embryos in Nature magazine in April 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
